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Association of Left Atrial Function Index with Atrial Fibrillation and
Cardiovascular Disease: The Framingham Offspring Study
Mayank Sardana, MBBS; Darleen Lessard, MS; Connie W. Tsao, MD; Nisha I. Parikh, MD, MPH; Bruce A. Barton, PhD; Gregory Nah, MA;
Randell C. Thomas, MD; Susan Cheng, MD; Nelson B. Schiller, MD; Jayashri R. Aragam, MD; Gary F. Mitchell, MD; Aditya Vaze, MD;
Emelia J. Benjamin, MD, ScM; Ramachandran S. Vasan, MD; David D. McManus, MD, ScM
Background-—Left atrial (LA) size, a marker of atrial structural remodeling, is associated with increased risk for atrial ﬁbrillation
(AF) and cardiovascular disease (CVD). LA function may also relate to AF and CVD, irrespective of LA structure. We tested the
hypothesis that LA function index (LAFI), an echocardiographic index of LA structure and function, may better characterize adverse
LA remodeling and predict incident AF and CVD than existing measures.
Methods and Results-—In 1786 Framingham Offspring Study eighth examination participants (mean age, 669 years; 53%
women), we related LA diameter and LAFI (derived from the LA emptying fraction, left ventricular outﬂow tract velocity
time integral, and indexed maximal LA volume) to incidence of AF and CVD on follow-up. Over a median follow-up of
8.3 years (range, 7.5–9.1 years), 145 participants developed AF and 139 developed CVD. Mean LAFI was 34.512.7. In adjusted
Cox regression models, lower LAFI was associated with higher risk of incident AF (hazard ratio=3.83, 95% conﬁdence
interval=2.23–6.59, lowest [Q1] compared with highest [Q4] LAFI quartile) and over 2-fold higher risk of incident CVD
(hazard ratio=2.20, 95% conﬁdence interval=1.32–3.68, Q1 versus Q4). Addition of LAFI, indexed maximum LA volume, or LA
diameter to prediction models for AF or CVD did not signiﬁcantly improve model discrimination for either outcome.
Conclusions-—In our prospective investigation of a moderate-sized community-based sample, LAFI, a composite measure of LA
size and function, was associated with incident AF and CVD. Addition of LAFI to the risk prediction models for AF or CVD, however,
did not signiﬁcantly improve their performance. ( J Am Heart Assoc. 2018;7:e008435. DOI: 10.1161/JAHA.117.008435.)
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I ncreased left atrial (LA) size and impaired phasic functionare distinct echocardiographic phenotypes that capture
different aspects of LA remodeling.1 Measures of increased
LA size, including anteroposterior LA diameter, area, or
volume, are measures of LA structural remodeling.1 Adverse
atrial structural remodeling has been associated with cardio-
vascular disease (CVD) and atrial ﬁbrillation (AF) risk
factors, including advancing age, hypertension, and diabetes
mellitus.2–13 Although measures of LA structural remodeling
have been associated with incident AF and CVD, associations
have been modest, and these measures do not incrementally
improve clinical AF and CVD risk prediction tools.2–12,14,15
Intermediate phenotypes that characterize functional LA
remodeling may potentially enhance AF and CVD risk
prediction. Recent reports have emphasized that impaired
LA phasic function is associated with incident and recurrent
CVD and AF, independent of LA size.16–19 However, the
incremental predictive value of functional LA remodeling over
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clinical prediction models is currently unknown. Furthermore,
LA function is strongly correlated with LA structure and is also
inﬂuenced by left ventricular (LV) systolic function.9,20 In this
context, the LA function index (LAFI) has been advocated as a
composite echocardiographic measure of both LA structure
and function that also adjusts for LV systolic function.21 LAFI
can be derived using LA and LV measures obtained routinely
as part of standard 2-dimensional echocardiography.21 Recent
data suggest that LAFI is strongly associated with risk for
developing AF recurrence, heart failure, and stroke in select
CVD-based samples.22–25 We recently reported on the
distribution of LAFI as well as its clinical and echocardio-
graphic correlates in the community-based FHS (Framingham
Heart Study) Offspring Cohort.26 In the current investigation,
we related LAFI to incident AF and CVD in FHS Offspring
participants and assessed its incremental contribution to
prediction of these outcomes.
Methods
The data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Sample
The Framingham Offspring Study is a longitudinal, community-
based cohort study.27 Starting in 1971, the children of the
Table 1. Baseline Characteristics of Study Participants and Excluded Participants
Variable
Study Participants
(N=1786)
Excluded Participants
(N=1102) P Value
Age, y 669 669 0.21
Women 957 (54%) 612 (56%) 0.33
Body mass index, kg/m2 285 296 0.006
Current smoker 171 (10%) 90 (8%) 0.20
Systolic blood pressure, mm Hg 12817 12918 0.19
Diastolic blood pressure, mm Hg 7310 7410 0.011
Antihypertensive medication use 938 (53%) 606 (55%) 0.21
Diabetes mellitus 279 (16%) 165 (15%) 0.63
Prevalent AF 133 (8%) 77 (7%) 0.64
Prevalent heart failure 43 (2%) 32 (3%) 0.42
Prevalent CVA or TIA 79 (4%) 43 (4%) 0.49
Prevalent coronary heart disease 192 (11%) 117 (11%) 0.90
Estimated glomerular filtration rate
less than 60 mL/min per 1.73 m2
287 (16%) 182 (17%) 0.81
Total/HDL cholesterol ratio 3.471.05 3.491.07 0.68
Incident AF* 145 (9%) 102 (10%) 0.64
Incident CVD† 139 (9%) 82 (9%) 0.56
AF indicates atrial ﬁbrillation; CVA, cerebrovascular accident; CVD, cardiovascular disease; HDL, high-density lipoprotein; TIA, transient ischemic attack.
*Incident AF is reported for the participants who were free of AF at baseline.
†
Incident CVD is reported for the participants who were free of CVD at baseline).
Clinical Perspective
What Is New?
• This study investigated the prognostic signiﬁcance of left
atrial function index, a composite echocardiographic mea-
sure of atrial structural and functional remodeling in a
medium-sized community-based sample.
• Left atrial function index impairment was associated with an
increased risk of developing incident atrial ﬁbrillation and
cardiovascular disease, independent of validated clinical risk
prediction scores and echocardiographic measures of
adverse cardiac remodeling.
What Are the Clinical Implications?
• Although the left atrial enlargement is widely utilized
clinically as a measure of left atrial remodeling, our ﬁndings
suggest an independent association of impaired left atrial
function index with adverse outcomes even in the presence
of normal left atrial size.
• Left atrial function index can be measured using widely
available 2-dimensional echocardiography.
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original cohort of the FHS and their spouses were enrolled
and have been evaluated every 4 to 8 years. Transthoracic
echocardiography was performed in 2888 participants with
digital image acquisition during their eighth examination cycle
(2005–2008).28 After excluding participants with absent or
poor imaging of the atrium (n=1093), and moderate to severe
or greater degrees of mitral regurgitation (n=9), 1786
participants remained eligible for the present analysis.
Characteristics of FHS participants who were included in
comparison with those excluded are presented in Table 1. For
incident AF outcome analyses, participants with history of
baseline AF were excluded, whereas for CVD outcome
analyses, the participants with history of baseline CVD were
excluded. Methodology for the ascertainment of cardiovascu-
lar risk factors, CVD, and AF are presented in Data S1.
The protocol for the FHS Offspring Study was approved by
the Boston University Medical Center Institutional Review
Board, and all analyses were approved by the University of
Massachusetts Medical School. All participants provided
written informed consent.
Echocardiographic Measurements
Routine M-mode and 2-dimensional echocardiography were
performed at the eighth examination cycle using a standard
protocol as described previously.28 M-mode measurements
were made using the leading-edge technique, and the ﬁnal
measureswere derived by averaging themeasurements over≥3
cardiac cycles. For the current investigation, we used the
following end-diastolic M-mode measurements in the paraster-
nal long axis view: LV septal wall thickness (SWTd), posterior
wall thickness (PWTd), LV internal diameter (LVIDd), and LA
anteroposterior diameter (LAD). LV mass was calculated
by using a previously validated formula: 0.8 [1.04
(LVIDd+SWTd+PWTd)
3(LVIDd)3]+0.6 g.29 In the apical-2 cham-
ber view, LV end-diastolic and end-systolic volumes were
measured using Simpson’s method. Stroke volume was calcu-
lated as (LV end-diastolic volumeLV end-systolic volume), and
LV ejection fraction was calculated as (Stroke volume/LV end-
diastolic volume)9100. LV outﬂow tract (LVOT) diameter was
measured in the parasternal long-axis view.30 LVOT velocity-
time integral (LVOTVTI) was calculated by dividing the stroke
volume by LVOT area (3.149(LVOT diameter/2)2).
Echocardiographic image acquisition was performed with
settings optimal for LV assessment. For LA volume measure-
ment, 2 sonographers converted saved images into a digital
format. The Digisonics DigiView System Software (version
3.7.9.3; Digisonics Inc, Houston, TX) was then used by 1 of 2
FHS sonographers to measure LA volumes. Maximum and
minimum LA volumes (LAmax, LAmin) were derived by
Table 2. Baseline Clinical and Echocardiographic Characteristics of Study Participants by Sex-Speciﬁc LAFI Quartile Groups
Variable LAFI Quartile 1 (N=446) LAFI Quartile 2 (N=446) LAFI Quartile 3 (N=446) LAFI Quartile 4 (N=446) P Value
LAFI, meanSD 19.95.6 302.6 37.13 51.18.8 <0.001
Age, y 709 669 659 648 <0.001
Body mass index, kg/m2 27.85 28.15 28.15.3 28.35.4 0.58
Current smoker 42 (9) 43 (10) 41 (9) 45 (10) 0.97
Systolic blood pressure, mm Hg 13019 12917 12716 12816 0.08
Diastolic blood pressure, mm Hg 7111 7310 7310 749 <0.001
Antihypertensive agent use 302 (67) 228 (51) 207 (46) 201 (45) <0.001
Diabetes mellitus 97 (22) 61 (14) 62 (14) 59 (13) <0.001
Prevalent AF 85 (19) 21 (5) 16 (3) 11 (2) <0.001
Prevalent heart failure 31 (7) 3 (1) 3 (1) 6 (1) <0.001
Prevalent CVA or TIA 39 (9) 14 (3) 11 (2) 10 (2) <0.001
Prevalent peripheral arterial disease 21 (5) 11 (2) 8 (2) 6 (1) 0.007
Prevalent coronary heart disease 80 (18) 43 (10) 36 (8) 33 (7) <0.001
10-y FHS CVD risk, %* 3119 2517 2316 2216 <0.001
CHARGE-AF risk, %† 8.710.3 5.66.9 4.95.9 4.35.8 <0.001
AF indicates atrial ﬁbrillation; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; CVA, cerebrovascular accident; CVD, cardiovascular disease; FHS, Framingham
Heart Study; LAFI, left atrial function index; TIA, transient ischemic attack.
*10-year FHS CVD risk was calculated for the participants who were free of CVD at baseline and had information available for individual components of FHS-CVD risk, which are age, male
sex, systolic blood pressure, antihypertensive medication use, current smoker, diabetes mellitus, and body mass index (n=1501).
†
CHARGE-AF risk was calculated for the participants who were free of AF at baseline and had information available for individual components of CHARGE-AF risk score, which are age, race,
height, weight, systolic blood pressure, diastolic blood pressure, current smoking, antihypertensive medication use, diabetes mellitus, heart failure, myocardial infarction, and left
ventricular hypertrophy and PR interval by ECG (n=1638).
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averaging the respective volumes in apical 2- and 4-chamber
views measured using the area-length method.31 LAmax index
was calculated by dividing LAmax by the body surface area.
LA emptying fraction was derived as ([LAmax – LAmin]/
LAmax)9100. LAFI was calculated using a previously derived
formula.21
LAFI ¼ LA emptying fraction LVOT-VTI
LAmax index
Statistical Analyses
The study sample was divided into 4 groups based on LAFI,
with quartile 1 (Q1) having the lowest LAFI values and quartile
4 (Q4) having the highest LAFI values. Because women have
higher LAFI,26 we generated sex-speciﬁc LAFI quartiles based
on previously observed distributions of LAFI among men and
women. Baseline characteristics of study participants are
presented as meansSD for continuous variables and as
numbers and percentages for nominal variables across each
LAFI quartile. Natural logarithmic transformation was per-
formed for the variables with skewed distribution (LV ejection
fraction and LV mass). Scatter plots were generated to depict
the correlation of LAFI with LAD, LAmax index, LV ejection
fraction, and LV mass.
We used Cox proportional hazards regression models to
study associations between LAFI and incident AF or CVD. The
assumption of proportionality of hazards was conﬁrmed for
each model. The Fine and Grey subdistribution method was
used to adjust the Cox proportional hazards models for
competing risk of death.32 The CHARGE-AF risk model used
in our analyses were previously validated using the Framingham
Offspring Cohort as predictors of incident AF.33,34 For CVD, we
utilized the 10-year FHS-CVDmodel, which has previously been
validated as a predictor of CVD in the FHS-Offspring cohort.35
We opted to use the FHS-CVD model instead of the contem-
porary American College of Cardiology and American Heart
Association’s 10-year pooled risk model36 because the pooled
risk model only estimates the risk of coronary death, nonfatal
myocardial infarction, and nonfatal stroke, whereas our CVD
outcome also included coronary insufﬁciency, angina, transient
ischemic attack, intermittent claudication, and heart failure, in
addition to coronary death, nonfatal myocardial infarction, and
nonfatal stroke. Because of our sample size and to reduce the
risk of overﬁtting our models, we adjusted for each individual’s
predicted risk score as a covariate instead of the individual
component variables in the regression models.
Two models were generated to examine the associations
between LAFI and AF. In model 1, we adjusted for CHARGE-AF
risk and in model 2 we adjusted for CHARGE-AF risk as well as
LV mass and ejection fraction. LAFI quartiles were included as
categorical variables in all models, and the hazards of AF were
calculated utilizing the highest quartile of LAFI as the
reference. In these models, only participants free from AF
Table 3. Association of LAFI With Incident AF in Cox Proportional Hazards Regression Model
Sample
No. of Eligible
Participants
No. of Incident
AF Events LAFI Quartile Events
Person-Years
Follow-up
P For Linear
Trend
Model 1 Model 2
Hazard Ratio
(95% Conﬁdence
Interval)
Hazard Ratio
(95% Conﬁdence
Interval)
Participants
free of AF
at baseline
1638 141‡ Q1 54 2224 <0.001 3.83 (2.23–6.59) 3.83 (2.23–6.59)
Q2 39 2918 2..41 (1.37–4.25) 2.39 (1.35–4.22)
Q3 30 3051 1.86 (1.04–3.33) 1.86 (1.04–3.33)
Q4 18 3277 1.00 1.00
Participants free
of CVD and AF
at baseline
1437 104 Q1 37 1836 <0.001 2.77 (1.53–5.01) 2.76 (1.53–4.99)
Q2 29 2596 2.02 (1.11–3.67) 1.98 (1.08–3.63)
Q3 21 2771 1.35 (0.72–2.53) 1.35 (0.72–2.54)
Q4 17 2997 1.00 1.00
Normal left atrial
volume (LAmax index
<34 mL/m2)
1242† 80 Q1 18 951 <0.01 3.52 (1.80–6.91) 3.71 (1.87–7.35)
Q2 23 2022 2.31 (1.21–4.43) 2.37 (1.22–4.59)
Q3 21 2687 1.44 (0.75–2.76) 1.50 (0.77–2.91)
Q4 18 3231 1.00 1.00
AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; LAFI, left atrial function index.
Model 1 was adjusted for CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology - atrial ﬁbrillation) risk. Model 2 was adjusted for model 1, ln(left ventricular mass),
and ln(left ventricular ejection fraction).
†
These participants were free of AF at baseline.
‡
A total of 145 participants developed incident AF events, but 4 did not have 1 or more of the variables required to calculate CHARGE-AF score reducing the eligible number of incident AF
events to 141.
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were included (n=1638). Two separate models were created
to examine the associations between LAFI and CVD. In model
1, we adjusted for FHS-CVD risk and in model 2 we adjusted
for FHS-CVD risk score as well as LV mass and ejection
fraction. In CVD-speciﬁc models, only participants free from
CVD were included (n=1501). Kaplan–Meier curves were
generated for both AF and CVD outcomes by quartile of LAFI.
To further reﬁne our understanding of LAFI and its relation
to relevant clinical outcomes in select subgroups, we
examined relations between LAFI and incident AF or CVD in
2 subgroups: (1) those free from both AF and CVD and
(2) those with normal LA volume index (LA volume index <34
mL/m2; n=1298).31 For both subgroups, we performed
secondary analyses using proportional hazards regression
analyses similar to those used in other analyses.
We examined the incremental beneﬁt of LAFI, LAD, or LAmax
index to existing clinical risk prediction tools for prediction of AF
and CVD, respectively, by examining change in model discrim-
ination based on Cox proportional hazards regressions models
including the appropriate clinical prediction models after
addition of LAFI, LAD, or LAmax index. We compared model
discrimination using the Nam and D’Agostino C-statistic.37 We
also calculated categorical net reclassiﬁcation improvement,
and IntegrativeDiscrimination Index tomeasure the incremental
discrimination by addition of LAFI, LAD, or LAmax index to the
clinical prediction models.38 Categories for net reclassiﬁcation
improvement were deﬁned a priori as tertiles of clinical risk
(lowest, intermediate, and highest) for both AF and CVD as
estimated by CHARGE-AF and FHS-CVD risk prediction models.
Finally, we also assessed model calibration using the Akaike
information criterion.39 A P value of <0.05 in 2-tailed tests was
considered statistically signiﬁcant. All statistical analyses were
performed using SAS (v9.3; SAS Institute Inc., Cary, NC) and
SPSS (version 24; IBM SPSS, Chicago, IL) software.
Results
Baseline demographic, clinical, and echocardiographic charac-
teristics of the study sample are presented by LAFI quartile in
Table 2. Participants included in our analyses were middle-
aged to older adults (mean age, 669 years; 54% women), and
the mean LAFI for the overall cohort was 34.512.7. Excluded
participants were more likely to have a larger body mass index,
reﬂecting the difﬁcult atrial imaging for larger individuals
(Table 1). For included participants, those with LAFI measures
in the lowest quartile (Q1) were older, had a greater burden of
cardiovascular and AF risk factors (including diabetes mellitus
and hypertension), and were more likely to have prevalent AF
and CVD when compared with participants with LAFI values in
the highest quartile (Q4). Predicted risk for incident AF and
CVD by clinical prediction models was higher for the partic-
ipants in Q1 when compared with Q4 participants.
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Figure 1. Kaplan–Meier curves depicting the risk of incident atrial ﬁbrillation stratiﬁed by quartiles of
LAFI. AF indicates atrial ﬁbrillation; LAFI, left atrial function index.
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Association of LAFI With Incident AF
Over a median follow-up of 8.3 years (interquartile range,
7.5–9.1), 145 participants developed new-onset AF. In a Cox
proportional hazards model adjusting for CHARGE-AF risk,
participants with LAFI values in Q1 were 3.8-fold more likely
to develop AF compared with participants in the Q4 (model 1,
Table 3). Even after adjustment for their CHARGE-AF risk
score, echocardiographic LV mass, and ejection fraction
(model 2, Table 3), lower LAFI remained associated with
higher hazards of incident AF (hazard ratio [HR] for AF among
participants in Q1 of LAFI compared with Q4=3.83; 95%
conﬁdence interval [CI], 2.23–6.59; P<0.001). Figure 1
depicts Kaplan–Meier curves for incident AF stratiﬁed by
the quartiles of LAFI. In a prespeciﬁed secondary subgroup
analysis including participants free from both AF and CVD,
lower LAFI was similarly associated with higher hazards for
incident AF (HR for Q1 versus Q4, 2.76; 95% CI, 1.53–4.99;
P<0.001; Table 3). Also, in participants with normal LA
volume index (<34 mL/m2), lower LAFI was associated with
higher hazards of incident AF (HR for Q1 versus Q4, 3.71; 95%
CI, 1.87–7.35; P<0.001; Table 3).
Association of LAFI With Incident CVD
Over a median duration of follow-up of 8.3 years (interquartile
range, 7.5–9.1), 139 participants developed CVD. In a Cox
proportional hazards regression model adjusting for 10-year
FHS-CVD risk, lower LAFI was associated with signiﬁcantly
higher hazards of incident CVD (HR for Q1 versus Q4 of LAFI,
2.20; 95% CI, 1.32–3.67; P=0.003; model 1, Table 4). Even
after including LV mass, ejection fraction, and FHS-CVD risk
score (model 2, Table 4) in Cox models, lower LAFI remained
associated with higher hazards of incident CVD (HR for Q1
versus Q4=2.20; 95% CI, 1.32–3.68; P=0.003). Kaplan–Meier
curves depicting the risk of CVD stratiﬁed by quartiles of LAFI
are presented in the Figure 2. In prespeciﬁed secondary
analyses including only participants free from both AF and
CVD, lower LAFI was associated with higher hazards for
incident CVD in multivariable-adjusted models (HR for Q1
versus Q4=2.37; 95% CI, 1.38–4.08; P=0.002; Table 4). In our
other prespeciﬁed secondary analyses including the partici-
pants with normal LAmax index, lower LAFI was associated
with higher risk of incident AF (HR for Q1 versus Q4=2.21;
95% CI, 1.15–4.24; P=0.018; Table 4).
LAFI, LA Size, and Other Measures of Cardiac
Remodeling
LAFI correlated poorly with LAD as well as other echocardio-
graphic variables (Figures 3 through 5), including LV ejection
fraction (Spearman rho=0.11; P<0.001), and LV mass
(Spearman rho=0.14; P<0.001). LAFI correlated inversely
with LAmax index (Spearman rho=0.71; P<0.001; Figure 6).
Despite its poor correlation with LAFI, LAD was associated
with incident AF and CVD (Tables 5 and 6).
Table 4. Association of LAFI With Incident CVD in Cox Proportional Hazards Regression Model
Sample
No. of Eligible
Participants
No. of Incident
CVD Events
LAFI
Quartile Events
Person-Years
Follow-up
P for Linear
Trend
Model 1 Model 2
Hazard Ratio
(95% Conﬁdence
Interval)
Hazard Ratio
(95% Conﬁdence
Interval)
Participants free
of CVD at baseline
1501 139 Q1 47 2295 <0.001 2.20 (1.32–3.67) 2.20 (1.32–3.68)
Q2 35 3025 1.58 (0.93–2.69) 1.57 (0.92–2.67)
Q3 34 3128 1.49 (0.87–2.54) 1.49 (0.87–2.54)
Q4 23 3343 1.00 1.00
Participants free
of CVD and AF
at baseline
1443 126 Q1 40 2071 <0.001 2.36 (1.37–4.05) 2.37 (1.38–4.08)
Q2 33 2945 1.66 (0.95–2.89) 1.65 (0.95–2.87)
Q3 32 3060 1.57 (0.90–2.73) 1.56 (0.90–2.73)
Q4 21 3314 1.00 1.00
Normal left atrial
volume (LAmax index
<34 mL/m2)
1149† 90 Q1 17 972 0.018 2.17 (1.14–4.12) 2.21 (1.15–4.24)
Q2 23 2166 1.44 (0.80–2.59) 1.45 (0.80–2.61)
Q3 27 2750 1.34 (0.77–2.35) 1.36 (0.77–2.40)
Q4 23 3290 1.00 1.00
AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; LAFI, left atrial function index.
Model 1 was adjusted for FHS-CVD risk. Model 2 was adjusted for model 1, ln(left ventricular mass), and ln(left ventricular ejection fraction) .
†
These participants were free of CVD at baseline.
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Improvement in Risk Prediction by Clinical
Prediction Models With Addition of LAFI, LAD,
and LAmax index
In Cox-proportional hazards models, CHARGE-AF score
demonstrated excellent performance for predicting AF in our
sample (C-statistic=0.733). Despite the association of LAFI
and LAD with incident AF in models including CHARGE-AF
score, neither the addition of LAFI nor LAD signiﬁcantly
improved risk prediction models (C-statistic differ-
ence=0.031 for LAFI and 0.009 for LAD; Table 7).
Similarly, the addition of LAmax index to CHARGE-AF score
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Figure 2. Kaplan–Meier curves depicting the risk of incident cardiovascular disease stratiﬁed by quartiles
of LAFI. CVD indicates cardiovascular disease; LAFI, left atrial function index.
Figure 3. Scatter plot depicting the correlation of LAFI with LA
dimension. LA indicates left atrium; LAFI, left atrial function index.
Figure 4. Scatter plot depicting the correlation of LAFI with left
ventricular ejection fraction. LAFI indicates left atrial function
index; LVEF, left ventricular ejection fraction.
DOI: 10.1161/JAHA.117.008435 Journal of the American Heart Association 7
LAFI, AF and CVD in FHS Sardana et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
did not improve the risk prediction (C-statistic differ-
ence=0.037). We also observed no signiﬁcant change in
categorical net reclassiﬁcation improvement or Integrative
Discrimination Index with addition of LAFI, LAD, or LAmax
index to clinical prediction models. We observed minimal
reduction in the Akaike information criterion (lower Akaike
information criterion indicating better model ﬁt): 38-point
reduction with addition of LAFI; 74-point reduction with
addition of LAD; and 34-point reduction with addition of
LAmax to clinical prediction models. C-statistic of LAFI alone
for prediction of AF was 0.638, whereas the C-statistic values
for LAD and LAmax index were 0.671 and 0.635, respectively
(Table 8). When LAFI, LAD, or LAmax index was added to a
baseline risk model with CHARGE-AF risk score and other
echocardiographic variables (LV mass and ejection fraction),
there was no signiﬁcant improvement in AF risk discrimination
(Table 9).
For CVD prediction, 10-year FHS-CVD risk also demon-
strated good performance for predicting CVD events in our
sample (C-statistic=0.682). We observed no signiﬁcant change
in C-statistic with addition of LAFI, LAD, or LAmax index to
clinical prediction models (C-statistic change=0.004 for LAFI,
0.004 for LAD, and 0.004 for LAmax index; Table 7).
Furthermore, there was no signiﬁcant reclassiﬁcation of CVD
risk prediction by clinical prediction models with the addition
of LAFI, LAD, or LAmax index. We observed minimal change in
Akaike information criterion with the addition of LAFI, LAD, or
LAmax index to the clinical prediction models (4-point
reduction with addition of LAFI, 48-point reduction with
addition of LAD, and 8-point reduction with addition of LAmax
index). C-statistic of LAFI alone for prediction of CVD was
0.583, whereas the C-statistic values for LAD and LAmax index
were 0.595 and 0.605, respectively (Table 8).
Discussion
In our prospective analysis of a community-based sample, LAFI
was associated with incident AF and CVD, which persisted after
adjustment for clinical prediction scores and echocardio-
graphic measures associated with AF and CVD, respectively.
LAFI remained associated with AF and CVD among those with
normal LA size, supporting the hypothesis that measure of LA
functional impairment adds to prediction of AF and CVD events
beyond LA structure. LAFI, however, did not improve the model
discrimination or reclassiﬁcation of the risk for either AF or CVD
predicted by clinical risk estimators. Similar to LAFI, LAD was
associated with incident AF and CVD events and was measur-
able in the majority of participants with echocardiographic
images suboptimal for the measurement of LA volumes,
suggesting that LAD remains a valid and clinically relevant
marker of LA remodeling and cardiovascular risk.2 Similar to
LAFI, LAD and LAmax index failed to improve the performance
of the clinical risk prediction models for AF or CVD.
LAFI as a Composite Echocardiographic Marker
of LA Remodeling
LA volume indexed to body surface area (LAmax index) is
currently recommended by consensus guidelines for assess-
ment of LA structure.31 LA emptying fraction and emptying
volume have also been examined as measures of LA reservoir
function.1 Compensatory changes in LA function might occur
with change in LA size.40 Furthermore, LV systolic function is
associated with LA reservoir function.20 LAFI is a composite
Figure 5. Scatter plot depicting the correlation of LAFI with left
ventricular mass. LAFI indicates left atrial function index; LV, left
ventricle.
Figure 6. Scatter plot depicting the correlation of LAFI with LA
volume index. LA indicates left atrium; LAFI, left atrial function
index.
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echocardiographic measure that adjusts LA function for LA
size, and attempts to isolate atrial remodeling from the
ventricular systolic function by incorporating LV stroke
volume (LVOT-VTI).21 Thus, LAFI may be better able to
account for both structural and functional LA remodeling than
other echocardiographic measures when they are considered
in isolation.
LA Remodeling and Incident AF
Echocardiographic LA anteroposterior diameter, maximal LA
volume, minimal LA volume, and LA emptying fraction
are associated with incident AF in community-based
samples2–5,8–10 and cohorts with CVD.6,7 In a past investiga-
tion involving participants in the original FHS cohort, every
5-mm increase in LAD was associated with increase in the
hazards of AF by 39% over a median follow-up of 7.2 years.2
More recently, in participants of the community-based MESA
(Multi-Ethnic Study of Atherosclerosis), higher LAmax index
(HR, 1.38; P=0.042) and lower LA emptying fraction (HR, 0.70;
P=0.020) as measured by magnetic resonance imaging were
associated with higher hazards of developing AF, after
adjusting for clinical risk factors and LV mass. Despite the
association of LA size with incident AF, the addition of LAD to
clinical risk models has not led to a signiﬁcant improvement in
model discrimination,12,15 whereas the incremental model
discrimination with the addition of LAmax or LA emptying
fraction to clinical risk scores has not been reported before.
Consistent with past investigations, we observed that
lower LAFI (ie, greater LA remodeling) was associated with
Table 5. Association of LA Diameter With Incident AF in Cox Proportional Hazards Regression Models
Sample
No. of Eligible
Participants
No. of Incident
AF Events LAD Quartile Events
Person-Years
Follow-up
P for Linear
Trend
Model 1 Model 2
Hazard Ratio
(95% Conﬁdence
Interval)
Hazard Ratio
(95% Conﬁdence Interval)
Participants
free of AF
at baseline
1638 141 Q1 24 3120 <0.001 1.00 1.00
Q2 29 2938 1.35 (0.79–2.30) 1.36 (0.80–2.33)
Q3 37 2972 1.47 (0.87–2.50) 1.49 (0.86–2.58)
Q4 51 2440 2.30 (1.42–3.71) 2.33 (1.39–3.88)
Participants free of
CVD and AF
at baseline
1437 104 Q1 21 2869 0.02 1.00 1.00
Q2 25 2672 1.43 (0.80–2.56) 1.38 (0.76–2.50)
Q3 29 2606 1.68 (0.95–2.98) 1.60 (0.87–2.94)
Q4 29 2055 1.64 (0.93–2.90) 1.56 (0.85–2.87)
AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; LAD, left atrial diameter.
Model 1 was adjusted for CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology - atrial ﬁbrillation) risk. Model 2 was adjusted for model 1, ln(left ventricular mass),
and ln(left ventricular ejection fraction).
Table 6. Association of LA Diameter With Incident CVD in Cox Proportional Hazards Regression Models
Sample
No. of Eligible
Participants
No. of Incident
CVD Events LAD Quartile Events
Person-Years
Follow-up
P For Linear
Trend
Model 1 Model 2
Hazard Ratio
(95% Conﬁdence
Interval)
Hazard Ratio
(95% Conﬁdence Interval)
Participants free
of CVD at baseline
1501 139 Q1 26 3212 <0.001 1.0 1.00
Q2 36 3026 1.42 (0.86–2.36) 1.41 (0.85–2.35)
Q3 26 3016 0.96 (0.56–1.65) 0.95 (0.55–1.65)
Q4 51 2536 1.84 (1.14–2.98) 1.83 (1.13–2.97)
Participants free
of CVD and
AF at baseline
1443 126 Q1 24 3177 <0.001 1.00 1.00
Q2 32 2985 1.37 (0.81–2.33) 1.37 (0.80–2.33)
Q3 26 2940 1.06 (0.61–1.84) 1.06 (0.60–1.85)
Q4 44 2288 1.98 (1.19–3.28) 1.97 (1.18–3.27)
AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; LAD, left atrial diameter.
Model 1 was adjusted for FHS-CVD risk. Model 2 was adjusted for model 1, ln(left ventricular mass), and ln(left ventricular ejection fraction).
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higher hazards of incident AF, even after adjustment for
clinical AF risk (CHARGE-AF risk)33 and the measures of LV
remodeling (mass and ejection fraction). Similarly, increase in
LAD was signiﬁcantly associated with AF in models analogous
to the LAFI models. However, the addition of LAFI, LAD, or
LAmax index to the models with CHARGE-AF risk score did
not lead to a signiﬁcant improvement in AF risk prediction,
likely because of the excellent overall performance of the
clinical AF risk prediction model in our sample and perhaps
also related to the moderate sample size.
CHARGE-AF risk is based on clinical and electrocardio-
graphic associates of incident AF (such as age, smoking,
weight, height, hypertension, diabetes mellitus, and prevalent
CVD).33 Our results suggest that LAFI detects subtle struc-
tural and functional LA derangements resulting from higher
intensity or duration of exposure to clinical AF risk factors
among individuals exposed to these risk factors. Although the
C-statistic of LAFI alone for prediction of AF was signiﬁcantly
lower than CHARGE-AF risk score, we noticed improvement in
model ﬁt (38-point reduction in AIC) with addition of LAFI to
the baseline CHARGE-AF model. Our ﬁndings suggest that
LAFI adds prognostic information to the clinical risk model,
but does not reclassify the risk of incident AF. Of note, LAD
was measurable in the majority of participants with image
quality suboptimal for the measurement of LA volumes (and
LAFI) and was associated with AF. Our ﬁndings suggest that
LAD should still be considered a clinically relevant marker of
atrial remodeling. Our observation that LAFI relates to AF
among those with normal LA size would suggest that LAFI
may represent an attractive intermediate phenotype to
consider in addition to clinical factors for studies examining
the effects of novel therapies to reduce or slow pathological
LA remodeling and prevent AF.41,42
LA Remodeling and Incident CVD
Past investigations involving participants from community-
based samples and cohorts with CVD have demonstrated a
signiﬁcant association between LA size and incident and
recurrent CVD.6–9,11,43 For example, among participants in
the original FHS cohort, every 10-mm increase in LAD was
associated with 1.4- to 2.4-fold higher hazards of stroke and
1.3- to 1.4-fold higher hazards of death over median follow-up
of 8 years, even after adjustment for CVD risk factors.11 Two
recent community-based studies have shown that LA reser-
voir function (LA emptying volume and fraction) is associated
with incident CVD and all-cause mortality, even after adjust-
ment for the measures of LV remodeling and LAmax.16,18
Table 7. Change in the Parameters of Model Discrimination With the Addition of LAFI, LA Diameter, or LA Volume Index to the
Hazards Models for Incident AF and CVD
Outcome Parameter Clinical Prediction Model* Clinical Risk+LAFI Clinical Risk+LA Diameter Clinical Risk+LA Volume Index
AF C-statistic 0.733 (0.679–0.787) 0.702 (0.638–0.767) 0.724 (0.669–0.779) 0.696 (0.633–0.759)
NRI†  0.123 0.072 0.104
IDI†  0.019 0.028 0.026
AIC 1910.3 1872.4 1835.7 1876.3
CVD C-statistic 0.682 (0.629–0.735) 0.686 (0.634–0.738) 0.678 (0.623–0.732) 0.686 (0.633–0.738)
NRI†  0.021 0.038 0.059
IDI†  0.004 0.004 0.009
AIC 1939.4 1934.8 1891.3 1931.2
AF indicates atrial ﬁbrillation; AIC, Akaike information criterion; CVD, cardiovascular disease; IDI, Integrated Discrimination Improvement; LAFI, left atrial function index; NRI, net
reclassiﬁcation index.
*CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology - atrial ﬁbrillation) model for AF, and FHS-CVD model for CVD.
†Outcomes at 5 years were used to calculate NRI and IDI.
Table 8. Association of LAFI, LA Diameter, and LA Volume Index in Hazards Models for Incident AF and CVD
Outcome Parameter LAFI LA Diameter LA Volume Index
AF C-statistic 0.638 (0.573–0.704) 0.671 (0.612–0.730) 0.635 (0.570–0.701)
AIC 1964.7 1923.2 1958.9
CVD C-statistic 0.583 (0.522–0.644) 0.595 (0.530–0.660) 0.605 (0.541–0.668)
AIC 1983 1929.1 1975
AF indicates atrial ﬁbrillation; AIC, Akaike information criterion; CVD, cardiovascular disease; LAFI, left atrial function index.
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Consistent with the past literature, we observed that LAFI was
associated with incident CVD, overall and among those with
normal LA volume, even after adjustment for clinical and
echocardiographic CVD risk factors. An increase in LAD was
similarly associated with an increased risk of CVD. However,
similarly to the AF models, addition of LAFI, LAD, or LAmax
index to the clinical CVD risk prediction models did not
improve model discrimination or reclassiﬁcation of predicted
CVD risk, again likely related to the excellent performance of
the FHS-CVD risk prediction instrument in our moderately
sized sample.
Strengths and Limitations
The results from our study should be analyzed in the context
of its strengths and weaknesses. We utilized data from a
medium-sized, community-based sample with rigorous CVD
risk factor and end point adjudication to examine associations
between an echocardiographic measure of LA remodeling
(LAFI) with incident AF and CVD events. However, our study
has several limitations. First, our sample was comprised
largely of participants of white ancestry and the application of
our results to the participants of other ethnicities needs
further investigation in multiethnic samples. Second, we
utilized 2-dimensional echocardiography to measure LA
volumes, which have lower correlation with magnetic reso-
nance imaging–measured volumes than those measured by
3-dimensional echocardiography.44 However, imaging time
and the lack of large studies with normative values limit the
widespread clinical use of 3-dimensional echocardiography
currently. Future studies should assess the prognostic value
of LAFI derived from 3-dimensional echocardiography in
community-based cohorts. Third, although we adjusted for LV
mass, and ejection fraction in our echocardiographic survival
models, echocardiographic measures of diastolic function
were not available and it is plausible that LV diastolic function
could mediate associations observed between LAFI with AF
and/or CVD. Fourth, nonvolumetric measures of atrial
function, such as atrial strain, were not available for our
analyses. Therefore, we were unable to directly compare the
predictive ability of LAFI with atrial strain. Fifth, although we
adjusted for clinical risk factors for AF and CVD using
previously validated risk scores, it is plausible that certain risk
factors (eg, obstructive sleep apnea, dietary practices, and
physical activity),45,46 which are not captured by clinical risk
scores, might have been differentially distributed in the
various LAFI quartile groups and could have, in part,
accounted for the association of LAFI with incident AF and/
or CVD.
Conclusions
In this investigation including data from participants in a
medium-sized, community-based sample with echocardio-
graphic imaging and rigorously adjudicated AF and CVD
events over an 8-year follow-up period, we observed strong
associations between LAFI, incident AF, and incident CVD in
adjusted models. Our ﬁndings suggest that LAFI captures
subtle and clinically relevant pathological changes in LA
structure and function. Our study ﬁndings also support the
notion that LAD and LAFI sit along the causal pathway from
risk factor exposure to AF and CVD. Future studies should
validate our ﬁndings in large, multiethnic cohorts with
longitudinal follow-up for AF and investigate whether LAFI
can be used to better target individuals at high clinical risk for
AF for further monitoring or AF prevention.
Table 9. Change in the Parameters of Model Discrimination With the Addition of LAFI, LA Diameter, or LA Volume Index to the
Hazards Models for Incident AF and CVD (Clinical and Echocardiographic Baseline Model)
Outcome Parameter Baseline Model Baseline Model+LAFI Baseline Model+LA Diameter Baseline Model+LA Volume Index
AF C-statistic 0.738 (0.684–0.792) 0.705 (0.642–0.769) 0.733 (0.680–0.787) 0.698 (0.636–0.761)
NRI†  0.088 0.113 0.078
IDI†  0.018 0.028 0.024
AIC 1913.3 1875.7 1837.4 1880.1
CVD C-statistic 0.684 (0.631–0.737) 0.689 (0.638–0.741) 0.678 (0.624–0.733) 0.686 (0.634–0.739)
NRI†  0.021 0.015 0.033
IDI†  0.004 0.004 0.009
AIC 1943.2 1938.7 1895.2 1935.2
AF indicates atrial ﬁbrillation; CVD, cardiovascular disease; NRI, net reclassiﬁcation index; IDI, Integrated Discrimination Improvement, LAFI, left atrial function index; AIC, Akaike
information criterion.
Baseline model for AF consisted of CHARGE-AF+ln(left ventricular mass)+ln(left ventricular ejection fraction). Baseline model for CVD consisted of FHS-CVD model for CVD+ln(left
ventricular mass)+ln(left ventricular ejection fraction).
†
Outcomes at 5 years were used to calculate NRI and IDI.
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SUPPLEMENTAL MATERIAL 
 
Data S1. 
 
Ascertainment of Prevalent Cardiovascular Risk Factors  
During each examination cycle, participants undergo a physician-administered medical history 
and cardiovascular-targeted physical examination, 12-lead electrocardiography and phlebotomy 
for assessment of CVD risk factors.1,2 For our study, left ventricular hypertrophy on 
electrocardiogram was defined using voltage-based criteria previously described.3 The PR 
interval was measured from the beginning of the P-wave to the end of the PR segment. Body 
mass index was calculated by dividing the weight in kilograms by the square of height in meters. 
The participants who reported smoking ≥1 cigarettes on a daily basis during the year preceding 
their Heart Study examination were considered current smokers. Participants were categorized to 
have hypertension if they had a systolic blood pressure ≥140 mmHg and/or a diastolic blood 
pressure ≥90 mmHg and/or were taking antihypertensive medications.4 Diabetes was defined as 
fasting plasma glucose ≥126 mg/dL and/or use of medications for lowering blood sugar. Cohorts 
for Heart and Aging Research in Genomic Epidemiology-AF (CHARGE-AF) risk and 10-year 
FHS-CVD risk were calculated using formulae previously validated in the Framingham 
Offspring Cohort.4, 5 
 
Ascertainment of AF Events 
The 12-lead electrocardiograms obtained during the FHS examination and from all inpatient and 
outpatient medical records were reviewed to ascertain for AF. Also, telemetry data obtained 
during hospitalizations was adjudicated for the presence of AF. In addition, inpatient telemetric 
data were adjudicated for possible AF. Potential AF cases were adjudicated by 2 or more FHS 
cardiologists.6 The participants were considered to have AF if a diagnosis of AF was made on 
any FHS or clinically obtained electrocardiogram, telemetry recordings, on a Holter monitor 
recording, or if a diagnosis of AF was documented by a treating physician in the hospital records. 
 
Ascertainment of CVD Events 
A committee comprised of three physicians reviewed the all pertinent medical records, including 
emergency and hospital notes, consultations, and outpatient visits and adjudicated CVD outcome 
events using previously published criteria.7 Events included in the composite CVD outcome 
included fatal or non-fatal coronary insufficiency, angina, myocardial infarction, transient 
ischemic attack, ischemic stroke, hemorrhagic stroke, intermittent claudication, heart failure, and 
cardiovascular death, as has previously been reported.8-10  
 
Definitions of CVD events 
Angina Pectoris  
Angina was defined by presence of brief recurrent episodes of chest discomfort (up to 15 mins in 
duration), precipitated by emotional stress or exertion, and relieved by rest or nitroglycerine.  
Coronarv Insufficiency  
Coronary insufficiency was defined by presence of prolonged ischemic chest pain (more than 15 
mins), with concomitant presence of transient ischemic ST segment and T wave changes on 
electrocardiogram, but with lack of Q waves on electrocardiogram or election of serum 
biomarkers of myocardial damage. 
Myocardial Infarction 
A myocardial infarction was determined to be present when 2 of 3 following findings were 
present in the medical record: (1) symptoms suggestive of cardiac ischemia; (2) increase in 
biomarkers of myocardial damage; and (3) serial changes in electrocardiograms suggesting the 
evolution of infarction. Old myocardial infarction was defined by the presence of a stable 
electrocardiographic changes including either a pathologic Q wave or loss of precordial R waves. 
An acute, new, or recent myocardial infarction documented in an autopsy report was also 
accepted as the evidence of a myocardial infarction.  
Intermittent Claudication 
Intermittent claudication was defined as presence of cramping discomfort in the calf that was 
clearly precipitated by walking some distance and relieved by a few minutes of rest. Symptoms 
were assessed using the standard structured forms by the study physicians for the uniformity of 
assessment. Additionally, a second study physician confirmed all the cause of suspected 
claudication during the examination.  
Heart Failure 
Congestive heart failure was defined by the concurrent presence of minimum of 2 major or 1 
major and 2 minor criteria. Other conditions capable of producing the symptoms and signs were 
considered while evaluating the findings.  
Major criteria: 
1) Paroxysmal nocturnal dyspnea 
2) Distended neck veins (in other than the supine position) 
3) Ventricular S3 gallop 
4) Rales  
5) Increasing heart size by X-ray  
6) Acute pulmonary edema described in hospital record 
7) Increased venous pressure (greater than 16 cm of water from the right atrium)  
8) Circulation time (greater than 24 seconds, arm to tongue)  
9) Hepatojugular reflux 
10) Pulmonary edema, visceral congestion, cardiomegaly on autopsy 
Minor criteria:  
1) Night cough  
2) Dyspnea with day-to-day activities 
3) Tachycardia (120 beats per minute or more) 
4) Bilateral ankle edema  
5) Hepatomegaly 
6) Pleural effusion 
7) Decrease in vital capacity by one-third from maximum record 
Arbitrary major or minor criterion: Weight loss (ten pounds or more in five days) while on 
therapy for congestive heart failure. 
Stroke 
The criteria for defining stroke included abrupt onset of a localizing neurologic deficit (such as 
hemiplegia, aphasia, homonymous hemianopia) lasting for more than 24 hours in duration. A 
neurologist and study physician reviewed hospital and clinic records to determine the presence 
and to differentiate the type of stroke (ischemic Vs. hemorrhagic).  
Transient Ischemic Attack 
A documented localizing neurologic deficit lasting for less than 24 hours in duration was 
considered a transient ischemic attack.  
Cardiovascular Death 
Death certificate, hospital, autopsy, and pathology records were reviewed by a panel of study 
physicians to ascertain the cause of death. Cardiovascular death was designated when the 
responsible cause was considered to be either coronary heart disease (angina pectoris, coronary 
insufficiency, myocardial infarction, intermittent claudication, congestive heart failure, stroke, or 
transient ischemic attack).  
 
Inter-observer and Intra-observer Variability in Measurement of LA volumes 
To reduce the inter- and intra-observer variability in LA volume measurement, serial quality 
control iterations were performed. Both sonographers measured LAmax and LAmin for 20 
randomly selected participants during each iteration cycle. Sonographers received training for 
LA volume measurement between serial iterations. Intra-observer and inter-observer coefficients 
of variation were less than 5% for both LAmax and LAmin. If images were deemed suboptimal 
for the measurement of LA volume (endocardial borders not well visualized, posterior wall of 
LA was not visualized, or recorded cardiac cycles contained a premature beat), the sonographer 
coded the measure as “inadequate”. LA volumes were then reviewed by a second sonographer or 
a study investigator (DDM) to confirm. Of note, the M-mode image quality was optimal for 
LAD measurement in nearly all of the included and excluded participants (Table 1).  
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